EuroPCR 2022 | GLOBAL SYMPLICITY Registry

The GLOBAL SYMPLICITY Registry is the largest study, with the longest followup, of real-world patients (real world data) presenting high blood pressure, treated with renal denervation. 

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

Time in Target Range (TTR), estimates the time a patient needs to control their blood pressure, and is an independent predictor of cardiovascular events. 

The aim of this registry, open, multicenter, and observational, was to assess the impact of improved TTR after radiofrequency renal denervation on cardiovascular outcomes, and estimate cardiovascular reduction associated to improved blood pressure control. 

3077 consecutive uncontrolled hypertensive patients, treated with the Symplicity™ (Flex o Spyral) radiofrequency renal denervation system, were included and followed up to 3 years. Cutoff values for TTR were office <140 mmHg and 24-hour ambulatory blood pressures <130 mmHg.

Mean age was 60±12 years, office BP was 166 mmHg ±25 and ambulatory BP was 154±19 mmHg; patients were treated with 4.9±1.7 antihypertensive medication classes. Office blood pressure saw a reduction vs. baseline of -13.2 at 6 months, -14 at one year, -15.3 at two years and -16.7 at 3 years (P<0.001). This progressive benefit was also seen in the ambulatory branch, with reduced hypertension values regardless the number of antihypertensives (p=0.007).

Read also: EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

TTR significantly and progressively increased at followup: 28.2% at 3 months vs. 34.9% at 3 years. As regards safety outcomes, there was a small number of events: creatinine elevation >50% in 1.3%, chronic kidney disease, advance stage, in 1.9% and the presence of new renal stenosis (>70%) in 0.3% of cases.

When looking at MACE, patients with TTR >50% presented fewer events compared against TTR 0-50% (2.9% vs 6.2%; P<0.0001). 10% TTR increase was associated to 16% MACE reduction. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presented by Mahfoud, F. en EuroPCR 2022, París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....